Schemes need a clear strategy for managing longevity risk

Increasing longevity is an important risk facing the trustees of defined benefit pension schemes. By offering a promise for life to members, they bear the risk that members live longer than expected.

2 minute read

a picture of a young hand holding an older one

Like other risks, trustees should quantify and assess any potential impact on their ability to pay out pensions. This can help them decide whether to manage these risks and how. As schemes mature and manage their investment risks, longevity risk can become more significant.

For many years, pension trustees have been plagued by the impact of rising longevity.

Today, thanks largely to improvements in healthcare and diet, a 65-year-old male can expect to live four years longer than was the case 20 years ago, according to data from the Office for National Statistics.

From the scheme’s perspective, longer lives correspond to worse funding positions.

The problem for scheme trustees is that longevity risks are harder to quantify than other risks they face.

Areas such as genetic medicine, 3D printed organs and better management of infectious diseases promise significant improvements in lifespan. Conversely, pollution, global warming and the challenges in managing obesity have the potential to upset this rosy picture for long lives.

The problem of gauging longevity risk is most acute for smaller schemes, where individual deaths have a more material impact, or where there is a significant proportion of liabilities in respect of a small proportion of members.

While longevity rates in general have been rising, there is evidence to suggest the pace of improvements has recently slowed.

For instance, the UK’s Institute and Faculty of Actuaries estimated that as at the start of 2018, a 65-year-old male would live on average 10 months less than expected three years earlier and a 65-year-old female 12 months less.

Managing longevity risk

All of this begs the question of what, if anything, trustees should do to mitigate their longevity risk.

In recent years, a number of ways to do this have emerged. However, none of these methods come without a cost, so before any decision can be taken schemes should attempt to analyse whether the benefits of employing one is likely to outweigh the costs.

The trustees might conclude the scheme should continue to bear longevity risk. If so, one prudent approach could be to target a financial buffer, which can act to offset any rise in longevity.

If instead they choose to mitigate longevity risk, the most established approach is to transfer it to an insurance company.

In the case of a buy-in, the insurance contract becomes an asset of the scheme, whereas a buyout contract fully discharges responsibility for paying pensions to the insurer. In either case the contracts are backed by a highly capitalised insurance regime.

Longevity swaps offer a different means of transferring risk. Here a pension scheme enters into a swap with an insurance company. In this case there is no money exchanged up front. Instead, the insurer agrees to pay the scheme if longevity rates rise, while a payment is made in the other direction if they fall.

The advantage for the trustees is that the scheme retains possession of its scheme’s assets – though some collateral is typically required – allowing the scheme to continue to invest to outperform liabilities.

Historically, longevity swaps have been the preserve of larger pension schemes. Over recent years, longevity swap arrangements have become more familiar, standardised and straightforward for a pension scheme to implement.

Schemes should ensure a clear strategy for managing longevity risk, and prepare to implement that plan when appropriate, including having complete and accurate member data.

Whichever route the trustees take, longevity should remain a regular feature of the ‘risk dashboard’ that trustees review periodically.

This article first appeared in Pensions Expert



Related views

Important information


Except where stated as otherwise, the source of all information is Aviva Investors Global Services Limited (AIGSL). Unless stated otherwise any views and opinions are those of Aviva Investors. They should not be viewed as indicating any guarantee of return from an investment managed by Aviva Investors nor as advice of any nature. Information contained herein has been obtained from sources believed to be reliable, but has not been independently verified by Aviva Investors and is not guaranteed to be accurate. Past performance is not a guide to the future. The value of an investment and any income from it may go down as well as up and the investor may not get back the original amount invested. Nothing in this material, including any references to specific securities, assets classes and financial markets is intended to or should be construed as advice or recommendations of any nature. Some data shown are hypothetical or projected and may not come to pass as stated due to changes in market conditions and are not guarantees of future outcomes. This material is not a recommendation to sell or purchase any investment.

The information contained herein is for general guidance only. It is the responsibility of any person or persons in possession of this information to inform themselves of, and to observe, all applicable laws and regulations of any relevant jurisdiction. The information contained herein does not constitute an offer or solicitation to any person in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it would be unlawful to make such offer or solicitation.

In Europe, this document is issued by Aviva Investors Luxembourg S.A. Registered Office: 2 rue du Fort Bourbon, 1st Floor, 1249 Luxembourg. Supervised by Commission de Surveillance du Secteur Financier. An Aviva company. In the UK, this document is by Aviva Investors Global Services Limited. Registered in England No. 1151805. Registered Office: St Helens, 1 Undershaft, London EC3P 3DQ. Authorised and regulated by the Financial Conduct Authority. Firm Reference No. 119178. In Switzerland, this document is issued by Aviva Investors Schweiz GmbH.

In Singapore, this material is being circulated by way of an arrangement with Aviva Investors Asia Pte. Limited (AIAPL) for distribution to institutional investors only. Please note that AIAPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIAPL in respect of any matters arising from, or in connection with, this material. AIAPL, a company incorporated under the laws of Singapore with registration number 200813519W, holds a valid Capital Markets Services Licence to carry out fund management activities issued under the Securities and Futures Act (Singapore Statute Cap. 289) and Asian Exempt Financial Adviser for the purposes of the Financial Advisers Act (Singapore Statute Cap.110). Registered Office: 1 Raffles Quay, #27-13 South Tower, Singapore 048583.

In Australia, this material is being circulated by way of an arrangement with Aviva Investors Pacific Pty Ltd (AIPPL) for distribution to wholesale investors only. Please note that AIPPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIPPL in respect of any matters arising from, or in connection with, this material. AIPPL, a company incorporated under the laws of Australia with Australian Business No. 87 153 200 278 and Australian Company No. 153 200 278, holds an Australian Financial Services License (AFSL 411458) issued by the Australian Securities and Investments Commission. Business address: Level 27, 101 Collins Street, Melbourne, VIC 3000, Australia.

The name “Aviva Investors” as used in this material refers to the global organization of affiliated asset management businesses operating under the Aviva Investors name. Each Aviva investors’ affiliate is a subsidiary of Aviva plc, a publicly- traded multi-national financial services company headquartered in the United Kingdom.

Aviva Investors Canada, Inc. (“AIC”) is located in Toronto and is based within the North American region of the global organization of affiliated asset management businesses operating under the Aviva Investors name. AIC is registered with the Ontario Securities Commission as a commodity trading manager, exempt market dealer, portfolio manager and investment fund manager. AIC is also registered as an exempt market dealer and portfolio manager in each province of Canada and may also be registered as an investment fund manager in certain other applicable provinces.

Aviva Investors Americas LLC is a federally registered investment advisor with the U.S. Securities and Exchange Commission. Aviva Investors Americas is also a commodity trading advisor (“CTA”) registered with the Commodity Futures Trading Commission (“CFTC”) and is a member of the National Futures Association (“NFA”). AIA’s Form ADV Part 2A, which provides background information about the firm and its business practices, is available upon written request to: Compliance Department, 225 West Wacker Drive, Suite 2250, Chicago, IL 60606.